Where does IDEAYA Biosciences, Inc.'s cash flow data come from?

Every line is extracted from IDEAYA Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$140.06M-23.2%	-$113.7M+29.3%	-$160.74M+51.6%	-$331.8M-8.0%	-$307.08M-11.9%
Depreciation and amortization	$2.79M+3.3%	$2.7M+5.8%	$2.55M+3.4%	$2.47M+4.0%	$2.37M-0.7%
Stock-based compensation	$50.41M+9.3%	$46.12M+5.3%	$43.81M+7.4%	$40.81M+5.5%	$38.67M+11.3%
Change in accounts receivable	——	$0+100%	-$2K-112%	$17K+467%	$3K—
Change in accounts payable	——	——	——	——	——
Change in accrued liabilities	——	——	$17.5M+35.8%	$12.89M-13.8%	$14.94M+38.4%
Change in other assets	$3.04M-62.2%	$8.03M+91.7%	$4.19M-18.5%	$5.14M+2.9%	$5M-18.8%
Change in deferred revenue	——	——	——	——	——
Non-cash operating lease expense	$1.82M-4.1%	$1.89M+27.2%	$1.49M-4.2%	$1.55M+2.6%	$1.51M+4.6%
Net cash from operating activities	-$85.93M-20.9%	-$71.1M+30.5%	-$102.26M+65.2%	-$293.71M-11.2%	-$264.11M-6.7%
Capital expenditures	$2.01M-15.3%	$2.37M-24.5%	$3.14M-11.7%	$3.55M-8.0%	$3.86M+0.1%
Purchases of investments	$545.29M-10.3%	$607.89M-14.2%	$708.79M-9.5%	$783.53M-4.5%	$820.74M-31.1%
Proceeds from maturities/sales of investments	$656.41M-3.5%	$680.23M-0.3%	$682.32M-1.9%	$695.67M-8.0%	$755.83M+9.1%
Net cash from investing activities	——	——	-$29.61M+67.6%	-$91.41M—	——
Proceeds from issuance of common stock	$56K—	$0-100%	$1.93M-99.3%	$276.23M+507%	-$67.83M-125%
Net cash from financing activities	$4.82M-83.8%	$29.78M-2.0%	$30.4M-90.4%	$316.61M-10.7%	$354.58M-47.7%
Net increase (decrease) in cash	——	——	——	——	$21.7M+130%
Interest paid	——	$0—	$0-100%	$3K-76.9%	$13K-48.0%
Accretion (Amortization) of Discounts and Premiums, Investments	$7.41M-25.7%	$9.98M-25.4%	$13.37M-20.2%	$16.75M-19.1%	$20.7M-10.9%
Accrued expenses and other liabilities	——	——	$17.5M+35.8%	$12.89M-13.8%	$14.94M+38.4%
Increase Decrease In Contract With Customer Asset And Liabilities	——	$5.97M+33.3%	$4.48M+50.0%	$2.99M+100%	$1.49M—
Increase Decrease In Operating Lease Liabilities	$2.63M+2.9%	$2.56M+41.9%	$1.8M+106%	$874K+398%	-$293K+78.6%
Increase (Decrease) in Prepaid Expense and Other Assets	$3.04M-62.2%	$8.03M+91.7%	$4.19M-18.5%	$5.14M+2.9%	$5M-18.8%
Operating lease right-of-use asset amortization	$1.82M-4.1%	$1.89M+27.2%	$1.49M-4.2%	$1.55M+2.6%	$1.51M+4.6%
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$656.41M-3.5%	$680.23M-0.3%	$682.32M-1.9%	$695.67M-8.0%	$755.83M+9.1%
Proceeds From Issuance Of Common Stock At The Market Offering Program Net Of Issuance Cost	——	——	——	——	——
Accrued payables for capital expenditures	$1.64M+50.2%	$1.09M+27.0%	$858K-59.0%	$2.09M+0.1%	$2.09M+29.1%
Increase Decrease In Contract With Customer Liability	——	——	——	——	——
Proceeds From Issuance Of Warrants	——	$0—	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	——
Unpaid At The Market Offering Program Costs In Accrued Liabilities	——	——	——	——	——
Free cash flow	-$87.93M-19.7%	-$73.47M+30.3%	-$105.39M+64.5%	-$297.26M-10.9%	-$267.98M-6.6%
Free cash flow	-$87.93M-19.7%	-$73.47M+30.3%	-$105.39M+64.5%	-$297.26M-10.9%	-$267.98M-6.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does IDEAYA Biosciences, Inc.'s cash flow data come from?: Every line is extracted from IDEAYA Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.